Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Cord Blood for Neurological Diseases
NCT05515419Phase 1Withdrawn
- Sponsor
- The Medical Pavilion Bahamas
- Start
- Jul 2025
- Primary completion
- Sep 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of allogeneic human umbilical cord blood in stroke and spinal cord injury (SCI), sponsored by The Medical Pavilion Bahamas. Primary endpoint: modified Rankin Scale at 12 months. Planned start Jul 2025; status: withdrawn.
02
Drugs
allogeneic human umbilical cord blood
03
Conditions
strokespinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05515419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515419.